AUA 2026 Prostate Cancer

Viewing 1-20 of 44 articles

AUA 2026: Prostate Cancer Screening, Detection, and Surveillance - Guidelines versus Real-World Practice versus Recent Evidence

AUA 2026: Locally Advanced and Recurrent Prostate Cancer Updates - Management of Biochemical Recurrence in 2026

AUA 2026: Localized Treatment - The Daily Triage of Grade Group 2 Prostate Cancer

AUA 2026: Role of Lymph Node Dissection at the Time of Radical Prostatectomy

AUA 2026: State-of-the-Art Lecture: Contemporary Perioperative Non-Opioid Pain Management Strategies

AUA 2026: Dehydrated Human Amniotic Membrane for Early Return of Erectile Function After Robotic Radical Prostatectomy: A 10-Year Journey and Lessons Learned

AUA 2026: Extraperitoneal Robot-Assisted Radical Prostatectomy with the Hugo™ RAS System: 100 Consecutive Cases, 1-Year Follow-up and Surgical Learning Curve Evaluation

AUA 2026: Cancer Extent and Cellularity but not Inflammatory Density are associated with MRI-Invisible Prostate Cancer on AI-Based Digital Pathology Deep Learning Models

AUA 2026: Radiographic Progression-free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial

AUA 2026: Duration of Treatment Suspension Among All Randomized Patients in EMBARK

AUA 2026: Safety of Rucaparib versus Docetaxel or Second-generation Androgen Receptor Pathway Inhibitor Therapy for Patients with Metastatic Castration-resistant Prostate Cancer and a BRCA mutation in TRITON3

AUA 2026: Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Reconstructed Individual Patient Data Analysis of the PEACE-3 Trial

AUA 2026: Real-World Darolutamide Safety and Effectiveness in Patients with Nonmetastatic Castration-Resistant Prostate Cancer with Comorbidities and Concomitant Medications: Post Hoc Analyses at DAROL Interim Analysis 4 (IA4)

AUA 2026: Impact of Anemia and Its Management on Quality of Life in Metastatic Castration-resistant Prostate Cancer Patients Treated with Talazoparib Plus Enzalutamide

AUA 2026: Redefining EMBARK-like Patients in the PSMA Era: Impact of PSMA-PET Restaging on Disease Classification and Management

AUA 2026: Real-world Characteristics, Treatment Utilization, and Outcomes Among Patients with Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Treated in Community Urology Centers in the US: A PRECISION Data Platform Study

AUA 2026: Real-World Outcomes of Triplet Intensification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer in Japanese Patients from the Prospective YUSHIMA Registry: Propensity-Weighted and Bayesian RMST Analysis

AUA 2026: Prostate-specific Antigen Endpoints in the Phase 3 PSMAddition Study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in Patients with PSMA-positive (PSMA+) Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

AUA 2026: Advanced Prostate Cancer - Doublet Versus Triplet: Who Needs Additional Treatment Intensification for mHSPC?

AUA 2026: Advanced Prostate Cancer - First-Line mCRPC/APMR: How Do I Select the Best Treatment for My Patient?

1
2
3